Abstract
Antiretroviral therapy has dramatically increased survival for HIV-infected individuals. As this population lives longer, coronary heart disease has become an important comorbid condition. Dyslipidemia in HIV-infected individuals is a complex condition, with multiple contributing factors including the HIV virus itself, individual genetic characteristics and antiretroviral therapy-induced metabolic changes. Effective management of dyslipidemia in this population is essential to reduce cardiovascular risk but presents multiple challenges due to interactions between antiretroviral therapy agents and lipid-lowering medications.
| Original language | English |
|---|---|
| Pages (from-to) | 447-462 |
| Number of pages | 16 |
| Journal | Clinical Lipidology |
| Volume | 6 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2011 |
| Externally published | Yes |
Keywords
- HIV-associated dyslipidemia
- drug interactions
- fibrates
- fish oil
- guidelines
- hypertriglyceridemia
- niacin
- statins